ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0039

Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases

Sophia Park1, Andre Rastegar2, Farzana Bhuyan3, Sara Alehashemi4, Danielle Fink2, Douglas Kuhns2, Adriana Almeida de Jesus5 and Raphaela Goldbach-Mansky6, 1NIAID, Bethesda, MD, 2NIH, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4NIH/NIAID/TADS, Clarksville, MD, 5NIAID, NIH, Silver Spring, MD, 6NIH/NIAID, Potomac, MD

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, cytokines, Gene Expression

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with systemic autoinflammatory diseases (SAIDs) present with chronic and acute elevations of proinflammatory serum cytokine and chemokine levels during exacerbations of disease flares. Compared to NOMID, patients (pts) with “autoinflammatory interferonopathies” present with elevated interferon (IFN) scores. We profiled serum cytokines/chemokines and whole blood transcriptional profiles in pts with the autoinflammatory diseases CAPS, CANDLE, SAVI, NEMO-NDAS versus healthy controls (HCs) and compared IFN cytokine and gene expression profiles between diseases.

Methods: All pts were enrolled into an IRB-approved natural history protocol (NCT02974595). RNA was extracted from pts and HC whole blood. Transcript counts for 28 Type I IFN, 9 IFNg, and 9 NF-kB-response genes were measured by NanoString, and standardized scores were calculated. Levels of 64 cytokines were measured in matched serum samples.

Results: In CANDLE, SAVI and NEMO-NDAS pts, the Type I IFN score significantly correlated with the NF-κB (r=0.792, r=0.615, r=0.696) and with the IFNγ score (r=0.615, r=0.859 and r=0.745). This was not observed in CAPS, SAAD and IL-18opathies; in these diseases the NF-κB score correlated significantly with the IFNγ score (r=0.615, r=0.859 and r=0.745). Interestingly, key inflammatory cytokines in NOMID were IL-1β, TNF and IL-12p70, which were most highly correlated with the NF-κB score. In SAVI, serum IL-1β, IL-6 and TNF best correlated with the Type I IFN score, which in CANDLE also included IL-18, IFNγ and IL-12 and in NEMO-NDAS was restricted to IFNγ and IL-12. Similarly, elevated markers of endothelial and neutrophil activation correlated with the NF-κB signature in NOMID and with the Type I IFN signature in CANDLE and NEMO-NDAS. Serum IFNα2 positively correlated with the Type I IFN score in CANDLE pts (r=0.74), while in NEMO-NDAS, serum IFNγ levels correlated best with the Type I IFN score, suggesting a potential role of IFNγ in contributing to Type I IFN score abnormalities. Whole blood cell IFNA2 transcription and serum levels only weakly correlated with serum levels in CANDLE and SAVI but IFNG transcription did not correlate with serum levels, suggesting non-hematopoietic production of IFNγ.

Conclusion: Distinct cytokine patterns distinguish active NOMID, SAVI, CANDLE and NEMO-NDAS pts, with proinflammatory cytokines correlating with the NF-κB score in NOMID and with the Type I IFN score in CANDLE and SAVI pts. Broader cytokine dysregulation in CANDLE and SAVI suggests complex immune dysregulation and likely reflect the contribution of organ inflammation to the serum cytokine measures obtained. Correlation with organ inflammation may allow the development of better biomarkers to monitor disease activity.


Disclosures: S. Park, None; A. Rastegar, None; F. Bhuyan, None; S. Alehashemi, None; D. Fink, None; D. Kuhns, None; A. Almeida de Jesus, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Park S, Rastegar A, Bhuyan F, Alehashemi S, Fink D, Kuhns D, Almeida de Jesus A, Goldbach-Mansky R. Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/type-i-and-type-ii-interferon-and-nf-%ce%bab-response-gene-scores-and-serum-cytokine-levels-in-patients-with-various-systemic-autoinflammatory-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-i-and-type-ii-interferon-and-nf-%ce%bab-response-gene-scores-and-serum-cytokine-levels-in-patients-with-various-systemic-autoinflammatory-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology